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Abstract: Heart failure patients with pulmonary edema presenting to the emergency department
(ED) require an effective approach to deliver sufficient oxygen and reduce the rate of intubation and
mechanical ventilation in the ED; conventional oxygen therapy has proven ineffective in delivering
enough oxygen to the tissues. We aimed to identify whether high-flow nasal cannula (HFNC)
therapy over time improved the respiratory rate (RR), lactate clearance, and certain arterial blood gas
(ABG) parameters, in comparison with conventional oxygen therapy, in patients with cardiogenic
pulmonary edema. This prospective, multi-institutional, and interventional study (clinical trial,
reference KCT0004578) conducted between 2016 and 2019 included adult patients diagnosed with
heart failure within the previous year and pulmonary edema confirmed at admission. Patients were
randomly assigned to the conventional or HFNC group and treated with the goal of maintaining
oxygen saturation (SpO2) ≥ 93. We obtained RR, SpO2, lactate levels, and ABG parameters at baseline
and 30 and 60 min after randomization. All parameters showed greater improvement with HFNC
therapy than with conventional therapy. Significant changes in ABG parameters were achieved
within 30 min. HFNC therapy could therefore be considered as initial oxygen therapy. Physicians
may consider advanced ventilation if there is no significant improvement in ABG parameters within
30 min of HFNC therapy.
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1. Introduction
Heart failure (HF) is a serious condition associated with high morbidity and mortality [1–3].
Acute pulmonary edema is a major complication of HF, and one of the causes of respiratory failure [3].
Importantly, acute cardiogenic pulmonary edema has an in-hospital mortality rate of approximately
10% and a one-year mortality rate of about 30% [4]. Many patients with HF develop acute pulmonary
edema and are admitted to the emergency department (ED) [2,3]. In addition to correction of the
underlying causes, the essential treatment for acute respiratory failure due to acute pulmonary edema
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aims to supply enough oxygen to the tissues and provide optional treatments including diuretics,
vasodilators, non-invasive positive pressure ventilation (NIPPV), and endotracheal intubation [5–7].
In the ED, conventional oxygen therapy with a nasal cannula or face mask is the most common for
patients with dyspnea, owing to high accessibility and convenience for both patients and medical
staff [8–10]. However, in some patients with acute respiratory failure, this conventional therapy alone
proves ineffective in delivering enough oxygen to the tissues [8–10]. Several supportive devices have to
be used to ensure that the physiological factors and symptoms improve [8–10]. To increase the efficacy
of treatment, the use of continuous airway positive pressure (CPAP) or noninvasive positive pressure
ventilation (NIPPV) may be required prior to endotracheal intubation [8–10]. The European Society of
Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure propose the
application of noninvasive mechanical ventilation, such as CPAP or NIPPV, to reduce hypercapnia and
acidosis and improve the breathing difficulty in dyspneic patients with a respiratory rate of more than
20 breaths/min and acute cardiogenic pulmonary edema (Class IIa recommendation) [1,11]. These
abovementioned factors have significantly reduced the need for tracheal intubation and mechanical
ventilation [3,12,13]. NIPPV can be used in the form of CPAP or bilevel NIPPV (BiPAP®, Respironics,
Inc, Murrysville, PA, USA) using face or nasal masks [14]. CPAP maintains constant positive airway
pressure throughout the respiratory cycle [14]. In contrast, bilevel NIPPV provides additional
inspiratory positive airway pressure and positive end expiratory pressure [14]. These devices are
more invasive than conventional oxygen therapy using a nasal cannula or face mask, and can pose
limitations for use in ED settings for patients with poor compliance, excessive mucus excretion, altered
consciousness, or facial anatomical abnormalities (due to surgery or injury) [5,12,15]. Moreover, CPAP
and BiPAP may cause discomfort, leading to failure of treatment and a reduction in cardiac index and
venous return in patients with low filling pressure and good ventricular performance [16–18].
The use of HFNC therapy may be limited in the patient affected by hypercapnic respiratory
failure because HFNC therapy has a minimal effect on reducing the CO2 levels by a washout of the
anatomical dead space [19]. In recent years, high-flow nasal cannula (HFNC) therapy has been used
as an effective approach for delivering sufficient oxygen to patients with acute respiratory failure
because this device can potentially generate positive airway pressure, decrease entrainment of ambient
air, and reduce the work of breathing [2,19]. Despite patient discomfort with high-flow oxygen
applications, the HFNC system can enhance the comfort and tolerability in patients by integrating
additional functions for humidification and warming of high-flow oxygen [2,19–21]. Based on the
aforementioned characteristics, the use of appropriate oxygen therapy can reduce the rate of intubation
and mechanical ventilation in the ED [8]
Previous studies have demonstrated that application of HFNC therapy could be a potential
therapeutic option in patients with acute respiratory failure [20]. Although several previous studies
on HFNC use in patients with acute respiratory failure have been conducted, few studies have
demonstrated the clinical effectiveness of HFNC therapy in HF patients with cardiogenic pulmonary
edema [2,20,22–24]. No international guideline has recommended the use of HFNC therapy in
patients with acute cardiogenic pulmonary edema. As research in this field is in the nascent stage,
further studies are needed to validate the clinical effectiveness of HFNC therapy in HF patients
with cardiogenic pulmonary edema. The prospective study by Makdee et al. demonstrated that
HFNC therapy improved the respiratory rate and oxygen saturation in patients (SpO2, measured
using pulse oximetry), without beneficial effects in ventilation and final outcomes [2]. They also
proposed that further studies using objective parameters such as blood gas analysis are required to
clarify beneficial effects and generalize the validity of the usefulness of HFNC therapy in HF patients
with cardiogenic pulmonary edema [2]. To the best of our knowledge, this is the first prospective,
randomized, controlled study involving HF patients with acute pulmonary edema to identify whether
HFNC therapy over time improves the respiratory rate (RR), lactate clearance, and parameters in
arterial blood gas (ABG, including partial pressure of oxygen (PaO2), partial pressure of carbon dioxide
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(PaCO2), pH, and HCO3− level), and whether HFNC therapy is superior to conventional oxygen
therapy in the early stages of ED admission.
2. Experimental Section
2.1. Study Design and Patients
This prospective, multi-institutional, and interventional study was performed at two EDs of
the Yonsei University College of Medicine affiliated to the Severance Hospital and the Gangnam
Severance Hospital between 10 July 2016 and 3 May 2019. The study protocol was reviewed and
approved by the institutional review boards of the Severance Hospital (No-1-2016-0030) and Gangnam
Severance Hospital (No-3-2016-0063) of the Yonsei University Health System. The trial was registered
at cris.nih.go.kr (Clinical Research information Service number (CRiS) Republic of Korea: KCT0004578).
Considering the severity of symptoms, written consent was obtained from patients or the legal caregivers
at entry into this study. If a patient without written consent recovered from respiratory failure, then a
newly written consent was obtained from the patient. The inclusion criteria were: age over 19 years
with a diagnosis of HF according to the New York Heart Association (NYHA) classification I–IV and the
American Heart Association/European Society of Cardiology (AHA/ESC) guidelines within one year of
admission; and acute pulmonary edema confirmed by a chest radiograph at admission. However, the
present study excluded patients who were diagnosed with HF at admission. Patients were excluded
based on the following criteria: non-cardiogenic pulmonary edema (acute respiratory distress syndrome,
ARDS); pneumonia; pregnancy; Glasgow Coma Scale score of 8 points or less; presence of a serious
congenital heart condition; on-going dialysis due to renal disease or glomerular filtration rate (GFR)
≤ 30; suspected myocardial infarction (ongoing chest pain, significant change of electrocardiograph,
and cardiac enzyme elevation); poor chance of survival due to a pre-existing condition; O2 supply
alone not being sufficient and the need for immediate invasive trachea management due to severity of
symptoms; reluctance to provide consent due to pre-existing conditions or do-not-resuscitate status;
cases of transfer from other healthcare institutions following stabilization of symptoms; and inability to
provide consent due to the severity of respiratory failure or absence of legal caregivers to authorize the
treatment. We performed a multicenter, randomized open-label trial. Patients were randomly assigned
to one of the two different treatment groups (conventional oxygen therapy vs. HFNC therapy) using
the permuted block of 4 as randomization method.
2.2. Intervention
In the conventional oxygen therapy group, oxygen therapy was commenced using a conventional
nasal cannula at a flow rate of >2 L/min. The flow rate was continuously adjusted within the
conventional nasal cannula or face mask to maintain an SpO2 of >93%. In the HFNC group, oxygen
therapy was applied using large-bore binasal prongs and a heated humidifier (MR850, Fisher & Paykel
Healthcare Limited, Auckland, New Zealand) with a flow rate of 45 L/min and fraction of inspired
oxygen (FiO2) of 1.0 at initiation (Optiflow, Fisher and Paykel Healthcare, Auckland, New Zealand).
The FiO2 (from 21% to 100%) and flow rate (up to 60 L/min) in the system were adjusted to maintain an
SpO2 of >93%. In the study protocol, all patients had to undergo treatment with the assigned modality
for at least 60 min. However, according to predetermined criteria of early termination, early intubation
and escalation of other devices were allowed if the patients had an intolerable response to the sustained
oxygen therapy with either the conventional nasal cannula or HFNC. Early termination criteria
included failure to tolerate the therapy (respiratory rate > 35 breaths/min, SpO2 < 90%, PaO2/FiO2 <
200 mmHg, pulse rate > 120 beats/min or a > 30% increase above the baseline and a noninvasively
measured pre-intervention mean arterial pressure > 30% higher than that at the baseline or signs of
respiratory distress (e.g., tachypnea, use of accessory muscles of respiration, and abdominal paradox),
and clinician judgements (when immediate intervention was required due to worsening of the levels
of anxiety, agitation, and consciousness compared to those at the pre-intervention timepoint). If one or
J. Clin. Med. 2020, 9, 1937 4 of 14
more of the early termination criteria were met, the oxygen therapy was escalated toward noninvasive
ventilation or converted directly to intubation for mechanical ventilation. In addition, all the patients
participating in the study were treated with the same standard and concomitant therapy, with a goal
of reaching SpO2 ≥ 93% and PaO2 of 80 mmHg, according to the established treatment guidelines
of the AHA for acute pulmonary edema [5]. We obtained RR, SpO2, and arterial blood gas analysis
(AGBA) data initially and 30 and 60 min after randomization. We also obtained the lactate levels
for lactate clearance initially and 60 min after randomization. We analyzed ABG and lactate levels
using Stat Profile pHOx Ultra Blood Gas Analyzer (Nova Biomedical, Waltham MA, USA). In this
study protocol, we could determine the baseline ejection fraction (EF) from within 6 months of ED
admission on the basis of the latest echocardiographic examination. We obtained the baseline EF
observed within 1 month preceding the ED from all subjects. In addition, we obtained the EF on
emergency echocardiography that was undertaken within 60 min after the intervention in the ED.
2.3. Study Outcomes
The primary outcome was to change the objective parameters, including changes in RR, parameters
of ABG, and lactate clearance in HF patients with acute pulmonary edema who were assigned into
two different treatment groups: HFNC therapy and conventional oxygen therapy. The secondary
outcome was to examine the rate of intubation within 24 h after ED admission, the intensive care unit
(ICU) admission rate, and all-cause mortality within 28 days of ED admission in each treatment group.
We reviewed the medical data from patient discharge and follow-up in the outpatient department that
were recorded in the electronic health records (EHRs) during the study period.
2.4. Statistical Analysis
The primary focus of the present study was to examine the changes in ABG levels and RR
while treating acute pulmonary edema in patients with HF who received either HFNC therapy or
conventional oxygen therapy. The number of participants required to identify clinical differences was
calculated as 66 participants (33 in each group), based on the minimal detectable differences applied in
a previous study that reported PaO2 82.5 ± 17.2 mm Hg for conventional oxygen therapy and PaO2
91.9 ± 7.4 mm Hg for HFNC therapy, with a power of 0.8, and an alpha of 0.05 [24]. We presented
demographic and clinical variables and descriptive statistics as medians and interquartile ranges
(IQRs), means and standard deviations, percentages, or frequencies, as appropriate. We compared
group differences using a chi-squared test or Fisher’s exact test for categorical variables and a t-test
or Mann–Whitney U test depending on the distribution of continuous variables. We evaluated the
serial changes in RR, parameters of ABG, and lactate clearance over time using a linear mixed model
as implemented in the MIXED procedure of SAS (version 9.2; SAS Institute, Cary, NC, USA) with
restricted maximum likelihood estimation [25]. This analysis uses the observed data from each patient
with no imputation for missing data [25]. Fixed effects were treatment (conventional oxygen therapy
and HFNC therapy), time of assessment, and the treatment by time interaction [25]. In this model,
we analyzed the interaction between the treatment group and time adjusted for baseline RR, lactate,
and ABG analysis (ABGA) parameters, as a treatment by time interaction indicates differential changes
in RR, lactate, and ABGA parameters over time depending on the treatment [25]. Additionally,
we performed post hoc analyses to estimate the time points at which the treatment effects differed
between the two groups [25]. In the post hoc analysis, the least square means of two groups were
estimated by the MIXED procedure at each time point and compared by the two-sample t-test [25].
In this model, we analyzed the interaction between the treatment group and the time-adjusted values
for the baseline RR, lactate levels, and ABGA parameters, because the treatment by time interaction
indicates differential changes in the RR, lactate levels, and ABGA parameters over time, depending on
the treatment [25,26]. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc.,
Cary, NC, USA) and MedCalc Statistical Software version 16.4.3 (MedCalc Software bvba, Ostend,
Belgium). All statistical tests were two-tailed, and p < 0.05 was considered indicative of statistical
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significance; moreover, 0.05 ≤ p < 0.1 was considered to represent a trend toward significance to
increase the sensitivity for the detection of potential selection biases.
3. Results
3.1. Characteristics of Study Subjects
A total of 215 patients were enrolled in this trial. Of these, 69 patients underwent randomization.
Two patients withdrew study consent during the trial. Finally, 33 patients were assigned to conventional
oxygen therapy, and 34 to HFNC therapy (Figure 1).
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Figure 1. Enrollment and randomization of study participants. GFR, glomerular filtration rate; DNR,
do not resuscitate.
Twenty-eight of the subjects were male (41.79%) and the mean age was 76± 9 years. Characteristics
of patients were similar between the two treatment groups. There were no major between-group
differences in the cotreatments, baseline ejection fraction (EF) within one month before ED admission
by the latest echocardiographic examination, and EF on emergency echocardiography conducted
within 60 min after intervention in the ED. However, systolic blood pressure, blood urea nitrogen
(BUN), and brain natriuretic peptide (BNP) levels were statistically higher in the HFNC group (Table 1).
The flow rate that resulted in the achievement of the goal of SpO2 > 93% was 4.36 ± 3.35 L/min in
the conventional O2 therapy group, whereas the flow rate and FiO2 were 47.58 ± 5.02 L/min and
57.39 ± 14.38, respectively, in the HFNC group.
3. . Study Outcomes
There were significant differences in the RR in the initial, 30 min, and 60 min measurements and
in the SpO2 at 30 and 60 min between the HFNC and conventional O2 therapy groups. With regard to
the ABGA parameters, there were significant between-group differences in the PaO2 and SpO2 at 30
and 60 min (T l 2).
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Table 1. Baseline characteristics of patients.
Variable
Total (n = 72) Conventional O2Therapy Group
High-Flow Nasal
Cannula Group p-Value
Mean ± SD or n (%) (n = 33, 49.3%) (n = 34, 50.7%)
Age (years) 76 ± 9 76 ± 9 77 ± 8 0.530
Male sex, number (%) 28(41.79) 13(39.39) 15(44.12) 0.695
Comorbidity (%)
Hypertension 40(59.70) 18(54.55) 22(64.71) 0.396
Diabetes mellitus 25(37.31) 11(33.33) 14(41.18) 0.506
Cardiovascular disease 9(13.43) 6(18.18) 3(8.82) 0.305
Chronic kidney disease 4(5.97) 2(6.06) 2(5.88) 0.999
Systolic blood pressure (mmHg) 148.96 ± 33.81 140.24 ± 22.41 157.47 ± 40.61 0.035 *
Diastolic blood pressure (mmHg) 86.67 ± 24.98 81.33 ± 13.71 91.85 ± 31.78 0.084 *
Heart rate (bpm) 95.51 ± 22.61 92.61 ± 19.33 98.32 ± 25.37 0.304
Body temperature (°C) 36.10 ± 3.26 35.43 ± 4.54 36.75 ± 0.56 0.106
Laboratory data **
White blood cell count (µL) 10855.22 ± 6803.40 10052.42 ± 5724.55 11634.41 ± 7715.25 0.345
Hemoglobin (g/dL) 11.66 ± 2.17 11.34 ± 1.99 11.976 ± 2.32 0.235
Hematocrit (%) 36.32 ± 6.73 34.99 ± 6.26 37.62 ± 6.99 0.109
Platelet count (103/µL) 216.97 ± 86.38 210.18 ± 92.31 223.56 ± 81.04 0.530
Blood urea nitrogen (mg/dL) 30.90 ± 17.85 25.86 ± 12.86 35.80 ± 20.66 0.021 *
Creatinine (mg/dL) 1.59 ± 1.07 1.40 ± 0.90 1.79 ± 1.20 0.139
Albumin (g/dL) 3.65 ± 0.53 3.66 ± 0.53 3.64 ± 0.53 0.881
Aspartate aminotransferase (IU/L) 38.27 ± 21.99 38.76 ± 20.15 37.79 ± 23.94 0.859
Alkaline phosphatase (IU/L) 26.73 ± 25.84 27.73 ± 27.07 25.77 ± 24.96 0.759
Total bilirubin (mg/dL) 1.14 ± 1.40 1.13 ± 1.31 1.15 ± 1.51 0.962
Sodium (mmol/L) 137.40 ± 5.44 137.55 ± 6.04 137.27 ± 4.87 0.835
Potassium (mmol/L) 4.44 ± 0.80 4.15 ± 0.75 4.73 ± 0.76 0.003 *
Chloride (mmol/L) 102.46 ± 5.97 103.15 ± 6.79 101.79 ± 5.07 0.351
Creatine kinase (U/L) 114.33 ± 87.24 105.73 ± 64.76 122.68 ± 104.92 0.428
Creatine kinase myocardial
bandisoenzyme (mcg/L) 4.19 ± 3.17 3.35 ± 2.72 5.02 ± 3.38 0.030 *
Troponin-I (mcg/L) 0.0842 ± 0.099 0.0674 ± 0.081 0.101 ± 0.112 0.169
Pro-brain natriuretic peptide (pg/mL) 8383.51 ± 14132.58 2662.59 ± 2092.40 13936.17 ± 18185.67 0.001 *
PaO2/FiO2 (initial) 337.4 3± 82.50 342.43 ± 94.17 332.58 ± 70.45 0.371
Echocardiography—previous ED visit
Ejection fraction (%) 46.10 ± 15.18 44.52 ± 15.30 47.65 ± 15.13 0.403
Valve disease 17(25.37) 7(21.21) 10(29.41) 0.441
Furosemide 67(100.00) 33(100.00) 34(100.00) 0.999
Dobutamine 48(71.64) 25(75.76) 23(67.65) 0.462
* p < 0.05, ED: emergency department, FiO2: fraction of inspired oxygen (FiO2), PaO2: partial pressure of oxygen.
** reference range, Table S1.
Table 2. Outcomes.
Variable
Total (n = 72) Conventional O2Therapy Group
High-Flow Nasal
Cannula Group p-Value
Mean ± SD or n (%) (n = 33, 49.3%) (n = 34, 50.7%)
Respiratory rate (bpm)
Initial 26.78 ± 3.99 25.18 ± 3.51 28.32 ± 3.86 0.001 *
30 min 23.75 ± 3.50 24.85 ± 3.19 22.68 ± 3.49 0.010 *
60 min 22.79 ± 3.72 24.30 ± 3.55 21.32 ± 3.32 0.001 *
SpO2 (%)
Initial 91.41 ± 5.89 92.55 ± 3.78 90.31 ± 7.29 0.120
30 min 95.69 ± 3.31 94.15 ± 3.26 97.18 ± 2.65 <0.001 *
60 min 95.94 ± 3.27 94.12 ± 3.25 97.71 ± 2.14 <0.001 *
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Table 2. Cont.
Variable
Total (n = 72) Conventional O2Therapy Group
High-Flow Nasal
Cannula Group p-Value
Mean ± SD or n (%) (n = 33, 49.3%) (n = 34, 50.7%)
Arterial Blood Gas Analysis
pH, initial 7.36 ± 0.09 7.38 ± 0.07 7.34 ± 0.11 0.063
pH, 30 min 7.39 ± 0.07 7.39 ± 0.06 7.39 ± 0.07 0.788
pH, 60 min 7.40 ± 0.06 7.40 ± 0.06 7.40 ± 0.06 0.595
PaO2, initial 70.86 ± 17.32 71.91 ± 19.78 69.84 ± 14.79 0.629
PaO2 30 min 87.79 ± 34.46 75.23 ± 19.87 99.98 ± 41.00 0.003 *
PaO2 60 min 90.62 ± 36.79 73.25 ± 13.02 107.47 ± 44.15 <0.001 *
PaCO2, initial 32.85 ± 10.44 30.89 ± 6.18 34.76 ± 13.17 0.129
PaCO2, 30 min 31.97 ± 8.21 32.61 ± 7.13 31.35 ± 9.20 0.532
PaCO2, 60 min 31.91 ± 7.22 32.30 ± 6.22 31.54 ± 8.14 0.670
SpO2 (%), initial 92.69 ± 3.79 92.55 ± 4.01 92.83 ± 3.63 0.765
SpO2, 30 min 95.30 ± 3.55 93.86 ± 3.38 96.71 ± 3.17 0.001 *
SpO2, 60 min 95.71 ± 3.07 93.99 ± 2.64 97.38 ± 2.51 <0.001 *
Lactate (mmol/L)
Initial 2.39 ± 2.02 2.01 ± 1.78 2.77 ± 2.20 0.126
60 min 1.82 ± 1.31 1.89 ± 1.55 1.75 ± 1.04 0.666
Echocardiography After ED visit
Ejection fraction (%) 40.15 ± 13.12 40.36 ± 15.23 39.94 ± 10.92 0.896
Valve disease 18(26.87) 8(24.24) 10(29.41) 0.633
Intubation 2(2.99) 1(3.03) 1(2.94) 0.999
ICU admission 18(26.87) 8(24.24) 10(29.41) 0.633
* p < 0.05, PaO2: partial pressure of oxygen, PaCO2: partial pressure of carbon dioxide, SpO2: peripheral
oxygen saturation.
A mixed model analysis of the present study demonstrated that the RR, lactate levels, SPO2, and
ABG parameters, including PaO2, PaCO2, and pH, had a significant interaction effect with regard to
the treatment group and time. This showed that the HFNC group showed a significant decrease in
lactate levels, RR, and PaCO2 as well as an increase in the PaO2, pH, and SpO2 over time. We found
changes in RR, lactate levels, SPO2, and ABG parameters from baseline to 60 min, depending on the
therapy groups (Figures 2 and 3).
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Figure 2. Linear mixed model of changes in respiratory rates (RR) and pulse oximetry (SpO2).
The graphs show interaction effects between time and treated group using the linear mixed model
(Group * Time). HFNC: high-flow nasal cannula.
We conducted a post hoc analysis to identify the timepoints of the different treatment effects for
the two study groups. In the HFNC-treated group, the treatment effects of RR, pH, PaO2, PaCO2, SPO2,
and lactate level improved, with statistical significance from the baseline to 60 min over time, indicating
greater therapeutic efficacy than in the conventional therapy group. The effects of treatment on the RR,
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pH, PaCO2, and SPO2 in the HFNC-treated group indicated significant improvements within 30 min,
with greater effectiveness than in the conventional therapy group. However, a statistically significant
effect on the HCO3 level was not found (Table 3). After adjusting the baseline value, lactate levels
revealed a borderline significant trend for the p-value, and the statistical significances of differences in
other parameters were similar to those identified on post hoc analysis (Table 4).J. Clin. Med. 2020, 9, x FOR PEER REVIEW 8 of 14 
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show interaction effects between time and treated group using linear mixed model (Group * Time),
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Table 3. Post hoc analysis to estimate the time points at which the treatment effects differed between
the 2 gr ups.
Group Post-Hoc p-Value Time Post-Hoc p-Value Group * Time Post Hoc
Conventional vs. HFNC Conventional vs. HFNC p-Value
Respiratory Rate
Initial 0.001 * Initial vs. 30 min 0.250 <0.001 * C vs. HFNC a d I i al vs. 30 min <0.001 *
30 min 0.010 * Initial vs. 1 h 0.037 * <0.001 * C vs. HFNC and Initial vs. 1 h <0.001 *
1 h 0.001 * 30 min vs. 1 h 0.064 <0.001 * C vs. HFNC and 30 min vs. 1 h 0.051
Arterial Blood Gas Analysis (ABGA), pH
Initial 0.064 Initial vs. 30 min 0.327 <0.001 * C vs. HFNC and Initial vs. 30 min 0.002 *
30 min 0.788 Initial vs. 1 h 0.330 <0.001 * C vs. HFNC and Initial vs. 1 h 0.003 *
1 h 0.595 30 min vs. 1 h 0.714 0.043 * C vs. HFNC and 30 min vs. 1 h 0.241
ABGA, PaCO2
Initial 0.130 Initial vs. 30 min 0.073 0.001 * C vs. HFNC and Initial vs. 30 min <0.001 *
30 min 0.532 Initial vs. 1 h 0.250 0.009 C vs. HFNC and Initial vs. 1 h 0.008
1 h 0.670 30 min vs. 1 h 0.648 0.779 C vs. HFNC and 30 min vs. 1 h 0.602
ABGA, PaO2
Initial 0.629 Initial vs. 30 min 0.520 <0.001 * C vs. HFNC and Initial vs. 30 min <0.001 *
30 min 0.003 * Initial vs. 1 h 0.809 <0.001 * C vs. HFNC and Initial vs. 1 h <0.001 *
1 h <0.001 * 30 min vs. 1 h 0.518 0.015 * C vs. HFNC and 30 min vs. 1 h 0.030 *
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Table 3. Cont.
Group Post-Hoc p-Value Time Post-Hoc p-Value Group * Time Post Hoc
Conventional vs. HFNC Conventional vs. HFNC p-Value
ABGA, HCO3
Initial 0.056 Initial vs. 30 min 0.871 0.089 C vs. HFNC and Initial vs. 30 min 0.188
30 min 0.220 Initial vs. 1 h 0.469 0.055 C vs. HFNC and Initial vs. 1 h 0.398
1 h 0.106 30 min vs. 1 h 0.289 0.831 C vs. HFNC and 30 min vs. 1 h 0.543
ABGA, SpO2
Initial 0.765 Initial vs. 30 min 0.020 * <0.001 * C vs. HFNC and Initial vs. 30 min 0.001 *
30 min 0.001 * Initial vs. 1 h 0.008 * <0.001 * C vs. HFNC and Initial vs. 1 h <0.001 *
1 h <0.001 * 30 min vs. 1 h 0.715 0.062 C vs. HFNC and 30 min vs. 1 h 0.288
Lactate
Initial 0.126 Initial vs. 60 min 0.661 <0.001 * C vs. HFNC and Initial vs. 60 min 0.020 *
60 min 0.664
* p < 0.05, C: conventional therapy group, HFNC: high-flow nasal cannula group, ABGA: arterial blood gas analysis,
PaO2: partial pressure of oxygen, PaCO2: partial pressure of carbon dioxide, SpO2: peripheral oxygen saturation.
Table 4. Analysis of the interaction between the treatment group and the time-adjusted values for
the baseline.
Conventional O2 Therapy Group HFNC Group
p-Value †
Estimated Mean (SE) Estimated Mean (SE)
Respiratory Rate
30 min–Initial −0.644(0.274) −5.346(0.27) < 0.001 *
1 h–Initial −1.189(0.386) −6.999(0.38) <0.001 *
1 h–30 min −0.546(0.29) −1.353(0.285) 0.051
Arterial Blood Gas Analysis (ABGA), pH
30 min–Initial 0.019(0.006) 0.038(0.006) 0.027 *
1 h–Initial 0.021(0.007) 0.053(0.007) 0.004 *
1 h–30 min 0.003(0.007) 0.015(0.01) 0.241
ABGA, PaCO2
30 min–Initial 1.003(0.766) −2.712(0.755) 0.001 *
1 h–Initial 0.688(0.885) −2.521(0.872) 0.013 *
1 h–30 min −0.315(0.687) 0.191(0.677) 0.602
ABGA, PaO2
30 min–Initial 3.6(5.143) 29.866(5.067) 0.001 *
1 h–Initial 1.622(5.444) 37.355(5.363) <0.001 *
1 h–30 min −1.979(3.042) 7.488(2.997) 0.030 *
ABGA, HCO3
30 min–Initial 0.195(0.394) 0.47(0.388) 0.625
1 h–Initial 0.568(0.372) 0.543(0.366) 0.963
1 h–30 min 0.373(0.349) 0.074(0.344) 0.543
ABGA, SpO2
30 min–Initial 1.223(0.453) 3.957(0.446) <0.001 *
1 h–Initial 1.354(0.353) 4.621(0.347) <0.001 *
1 h–30 min 0.13(0.355) 0.665(0.35) 0.288
Lactate
60 min–Initial −0.342(0.18) −0.801(0.177) 0.076
* p < 0.05, HFNC: high-flow nasal cannula group, ABGA: arterial blood gas analysis, RR: respiratory rate, PaO2:
partial pressure of oxygen, PaCO2: partial pressure of carbon dioxide, SpO2: peripheral oxygen saturation,
† Adjustment; baseline value of parameter. SE, standard error.
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There was no significant difference in the rates of endotracheal intubation within 24 h between
patients receiving conventional oxygen therapy (n = 1, 3.0%) and those with HFNC therapy (n = 1,
2.94%, p = 0.999). All endotracheal intubations were undertaken after the completion of the study
interventions. Therefore, patients were not excluded from this study merely due to the need for
intubation. In addition, there was no significant difference in ICU admission rate between the
conventional oxygen group (n = 8, 24.24%) and HFNC group (n = 10, 29.41%, p = 0.633). There was no
significant difference in the overall development of serious adverse events (no cardiac arrest occurred
before endotracheal intubation and during the study, and no pneumothorax and pneumomediastinum
developed during the study). No significant difference was found in all-cause mortality within 28 days
of ED admission between the two groups (no 28-day mortality developed in this study).
4. Discussion
We performed the present study to clarify the beneficial effects of HFNC therapy in ED patients
with cardiogenic pulmonary edema using objective parameters of RR, lactate levels, SPO2, and ABG
parameters. To the best of our knowledge, this is the first prospective, randomized, controlled study
involving HF patients with acute pulmonary edema to identify whether HFNC therapy improved
lactate clearance and objective parameters in arterial blood gas over time. In this study, we observed
that several objective parameters including RR, lactate levels, SpO2, and ABG parameters (PaCO2, pH,
PaO2, pH, HCO3–, and SpO2) in the HFNC-treated group clinically improved over time compared with
the conventional oxygen therapy group in patients with cardiogenic pulmonary edema. Although the
present study showed that significant changes in RR, pH, PaO2, PaCO2, and SPO2 in the HFNC-treated
group were achieved from the baseline to 60 min, clinically, HFNC therapy improved several parameters
including the RR, pH, PaCO2, and SPO2, from baseline to 30 min after admission and was more
effective than conventional oxygen therapy.
The application of HFNC therapy significantly improved oxygenation and decreased the RR in
patients with respiratory failure [20]. A retrospective study by Jeong et al. demonstrated that the use
of HFNC therapy could significantly increase the PaO2, pH, and SpO2 and decrease the PaCO2 and
RR in patients with hypercapnia in the ED [24]. In HFNC therapy, the high flow washes out carbon
dioxide from the anatomical dead space of nasopharynx and overcomes resistance against expiratory
flow [19,20,27,28]. This produces positive pressure within the nasopharyngeal space that is appropriate
for recruiting the collapsed alveoli or for increasing the lung volume (CPAP effect) despite its relatively
low pressure compared with closed systems [20,27,28]. HFNC therapy maintains a relatively constant
FiO2 because of the small difference between the high-flow oxygen that is delivered and the patient’s
inspiratory flow [20,27,28]. Patients feel comfortable and the mucociliary function remains good
because the HFNC can warm and humidify high flow [19,20,27,28]. Given the physiological benefits
of the HFNC, it is clear that HFNC therapy provides a constant FiO2 and O2 with the nasal cannula,
thereby reducing CO2 rebreathing, ensuring constant positive pressure, and providing a fresh O2
reservoir by washing out the nasopharyngeal dead space. Consequently, the HFNC can maintain
sufficient oxygenation by improving the respiratory load and gas exchange in cardiogenic pulmonary
edema [23,29]. We found that HFNC therapy could deliver effective oxygenation without major
complications or life-threatening adverse events.
Similar to previous studies, the present study also confirmed that HFNC therapy had beneficial
effects of change in objective parameters over time in HF patients with cardiogenic edema. In addition,
the benefits of the HFNC included greater comfort and tolerability than conventional oxygen therapy
because the HFNC system integrates humidification and warming of high-flow oxygen [2,30]. We did
not evaluate subjective comfort and clinical tolerability of HFNC in patients. Our study revealed a
significant decrease in RR over time after the use of HNFC in patients with cardiogenic pulmonary
edema. The application of the HFNC could bridge the gap between conventional oxygen therapy and
noninvasive and invasive mechanical ventilation [9].
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Makdee et al. suggested that the use of the high-flow nasal cannula in the ED significantly
decreased the RR and degree of dyspnea within 30 min [2]. Although the current study demonstrated
that significant changes in RR and PaO2 in the HFNC-treated group were achieved from the initial
timepoint to 60 min, most changes were achieved between baseline and 30 min. Clinically, the HFNC
improved several parameters including PaCO2, pH, and SpO2 between 0 and 30 min and was more
effective than conventional oxygen therapy. Considering our results and previous studies, if there is no
improvement in the objective parameters such as ABG and RR in 30 min after the use of the HFNC,
advanced ventilation devices including noninvasive and invasive mechanical ventilation should be
actively considered in HF patients with pulmonary edema.
No serious and life-threatening complications occurred in the HFNC-treated group. However,
similar to previous studies, HFNC therapy did not show more benefits compared to conventional
oxygen therapy with respect to endotracheal intubation within 24 h, ICU admission rate, and 28-day
mortality in HF patients with acute pulmonary edema. Nonetheless, it is noteworthy that the brain
natriuretic peptide (BNP) value was statistically higher in the HFNC group than in the conventional
O2 group in this study. BNP is a hormone that is secreted by the ventricle in response to increased
ventricular volume or pressure [31]. The BNP value is elevated when left ventricular systolic function
decreases; this elevation is proportional to the severity of HF according to the NYHA classification,
and can indicate the long-term prognosis in patients with heart failure [32]. As the pro-BNP value
was significantly higher in the HFNC group than in the conventional O2 group, the HFNC group may
have shown a greater degree of severity of heart failure at the time of ED admission. However, in this
study, we cannot exclude the possibility that the pro-BNP level could have affected clinical outcomes
such as ICU admission and 28-day mortality. Moreover, it was difficult to conduct a cardiopulmonary
exercise test and immediate echocardiography upon ED admission in the emergency setting of our
study, and therefore further prospective multicenter studies are required to validate the clinical utility
of the HFNC based on the HF severity of patients with cardiogenic pulmonary edema.
There are some limitations to this study. First, although this trial was prospectively conducted in
two institutions of Korea, the external validation and generalization of the benefits of HFNC therapy
are partially limited. Second, we enrolled adult patients diagnosed with HF according to NYHA
I–IV guidelines within one year of admission in this trial. The therapeutic effects of the HFNC are
difficult to generalize in the development of acute pulmonary edema in first diagnosed acute and
severe cases like acute myocardial infarction. Third, as the present study was conducted by adjusting
the FiO2 and flow rate with the goal of maintaining an SpO2 > 93%, we recorded FiO2 and flow
rate that achieved the stated goal. An ABGA was conducted in accordance with the predetermined
protocol. Therefore, we could not directly compare the clinical implications between ABGA parameters
and FiO2 or flow rate in each device. Further studies are needed to validate the impact of ABGA
parameters by adjusting the FiO2 or flow rate in each device for O2. Fourth, as the rate of the HFNC
increases, so does the positive pharyngeal pressure. The application of HFNC therapy was maintained
below 3 cmH2O of positive pharyngeal pressure even at a flow rate of 60 L/min with the mouth
open [27,33]. Roca et al. demonstrated that the application of HFNC therapy significantly decreased
the median inferior vena cava inspiratory pressure by approximately 20% from the baseline in patients
with New York Heart Association Class III heart failure [22]. These changes in the inferior vena
cava inspiratory collapse were reversible after HFNC withdrawal [22]. Nevertheless, there were no
significant changes in other echocardiographic or clinical variables [22]. Although we obtained the
data from echocardiographic studies conducted within 1 month before the ED admission and 60 min
after the intervention, to compare the pre- and post-intervention parameters, this study could not
completely clarify the positive or negative effects of positive end expiratory pressure (PEEP) of the
HFNC in HFNC-treated patients because we were unable to obtain the echocardiographic results
immediately before the intervention and after the ED admission. In order to clarify the benefits of the
HFNC, further prospective multicenter trials are required to validate the usefulness of HFNC therapy
in patients with cardiogenic pulmonary edema.
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5. Conclusions
Compared with conventional oxygen therapy, HFNC therapy could significantly improve several
objective parameters over time such as RR, lactate levels, and ABG reflection of oxygenation and
ventilation after ED admission in HF patients with acute pulmonary edema. The application of HFNC
therapy could replace conventional O2 therapy as initial effective oxygen therapy in patients with
cardiogenic pulmonary edema in the ED. In addition, we suggest that physicians consider advanced
ventilation devices if there is no significant improvement in several parameters in ABGA after HFNC
therapy in patients with cardiogenic pulmonary edema.
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